Expression of epidermal growth factor and androgen receptors in ovarian cancer.

Ovarian cancer is the second most common malignancy of the female reproductive tract. Approximately 50% of ovarian cancers have elevated levels of epidermal growth factor receptor (EGFR). This overexpression is correlated with a poor prognosis for patient survival. Ovarian cancers also express a number of sex steroid receptors. The androgen receptor (AR) is the predominant sex steroid receptor and is expressed in over 80% of ovarian cancers. We investigated whether a relationship exists between EGFR and AR in ovarian cancer. Sixty serous cystadenocarcinomas were analyzed for their relative levels of EGFR and AR by Western blot analysis. Data were analyzed by Student's t test and linear regression analysis for statistical significance. More than 98% of the tumors expressed detectable levels of EGFR, while 65% of the tumors expressed detectable levels of AR. The levels of EGFR (mean +/- SEM) were found to be significantly (P < 0.01) higher in AR+ (516 +/- 15) than in AR- (304 +/- 57) tumors. EGFR levels significantly correlated to AR levels (r = 0.49, P < 0.001). These results demonstrate an association between EGFR and AR levels in ovarian cancer. Whether this association represents a causal or a casual relationship remains to be determined.

[1]  C. M. Wilson,et al.  A and B forms of the androgen receptor are expressed in a variety of human tissues , 1996, Molecular and Cellular Endocrinology.

[2]  B. Karlan,et al.  Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. , 1995, American journal of obstetrics and gynecology.

[3]  B. Scoccia,et al.  Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta , 1995, Molecular reproduction and development.

[4]  E. Adashi.  The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. , 1994, Fertility and sterility.

[5]  G. Scambia,et al.  Significance of epidermal growth factor receptor in advanced ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Prins,et al.  Androgen receptor localization in different cell types of the adult rat prostate. , 1991, Endocrinology.

[7]  B. Scoccia,et al.  Gonadal and adrenal effects on hepatic epidermal growth factor receptor expression in a murine model. , 1991, Endocrinology.

[8]  T. Yamamoto,et al.  Evidence for the involvement of transforming growth factor alpha and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. , 1991, Cancer research.

[9]  R. Bast,et al.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor , 1991, American journal of obstetrics and gynecology.

[10]  J. Baak,et al.  Correlation between nuclear DNA content and steroid receptor status in ovarian cancer. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[11]  R. Bast,et al.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[12]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  B. Slotman,et al.  Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator , 1990, Cancer.

[14]  L. Wang,et al.  Human epidermal growth factor receptor residue covalently cross-linked to epidermal growth factor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. Slotman,et al.  Response to inhibition of androgen action of human ovarian cancer cells in vitro. , 1989, Cancer letters.

[16]  B. Slotman,et al.  Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. , 1988, Anticancer research.

[17]  J. Stolk,et al.  Androgen receptor predominance in human ovarian carcinoma. , 1987, Journal of steroid biochemistry.

[18]  S. Cohen,et al.  Epidermal growth factor , 1972, The Journal of investigative dermatology.

[19]  G. Sherbet,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER , 1985, The Lancet.

[20]  A. Ullrich,et al.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.

[21]  R. Weller,et al.  International Histological Classification of Tumours , 1981 .

[22]  O. Dodge,et al.  International Histological Classification of Tumours, No. 9. Histological Typing of Ovarian Tumours , 1974, British Journal of Cancer.

[23]  J. Vermorken,et al.  Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. , 1994, European journal of cancer.

[24]  A. Brinkmann,et al.  Mechanism of androgen action: recent observations on the domain structure of androgen receptors and the induction of EGF-receptors by androgens in prostate tumor cells. , 1989, Journal of steroid biochemistry.

[25]  G. Sherbet,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS AND ESTROGEN-RECEPTORS IN HUMAN-BREAST CANCER , 1985 .

[26]  P. Terranova,et al.  Factors regulating ovarian function , 1983 .